Novartis announces new data from PSMAddition

Novartis (NVS) announced new data from PSMAddition demonstrating improved prostate-specific antigen, PSA, responses with Pluvicto combined with standard of care, SoC, in PSMA-positive metastatic hormone sensitive prostate cancer, mHSPC. Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026. Results show that patients treated with Pluvicto experienced a higher frequency and depth of PSA response when combined with SoC compared to SoC alone. Risk of PSA progression was 58% lower in patients treated with Pluvicto plus SoC compared to SoC alone. Nearly all patients in both arms had substantial declines in PSA levels. However, more patients treated with Pluvicto plus SoC achieved a deep PSA reduction than those treated with SoC alone, as measured by PSA nadir of less than 0.2 ng/mL.